Mary Eileen Dolan to Prognosis
This is a "connection" page, showing publications Mary Eileen Dolan has written about Prognosis.
Connection Strength
0.306
-
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
Score: 0.110
-
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500.
Score: 0.058
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.027
-
Comparison of vaginal microbiota in gynecologic cancer patients pre- and post-radiation therapy and healthy women. Cancer Med. 2020 06; 9(11):3714-3724.
Score: 0.026
-
Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clin Cancer Res. 2020 06 15; 26(12):2891-2897.
Score: 0.026
-
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Res Treat. 2018 Feb; 168(1):207-220.
Score: 0.022
-
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393.
Score: 0.016
-
Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009 Apr 01; 23(7):877-89.
Score: 0.012
-
O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma. J Pediatr Hematol Oncol. 2003 Dec; 25(12):941-7.
Score: 0.009